Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

盘前交易 05-03 05:16:32 EDT

23.27

+0.77

+3.42%

盘前23.58

+0.31+1.33%

04:25 EDT

最高23.36	最低22.37	成交量121.87万
今开22.80	昨收22.50	日振幅4.40%
总市值22.44亿	流通市值22.17亿	总股本9,644万
成交额2,800万	换手率1.28%	流通股本9,529万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":23.27,"timestamp":1714680000000,"preClose":22.5,"halted":0,"volume":1218694,"hourTrading":{"tag":"盘前","latestPrice":23.58,"preClose":23.27,"latestTime":"04:25 EDT","volume":47,"amount":1108.579929,"timestamp":1714724749590},"delay":0,"floatShares":95290988,"shares":96438608,"eps":-5.42066,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.77,"latestTime":"05-03 05:16:32 EDT","open":22.8,"high":23.36,"low":22.37,"amount":27997905.473024,"amplitude":0.044,"askPrice":23.59,"askSize":13,"bidPrice":21.44,"bidSize":45,"shortable":3,"etf":0,"ttmEps":-5.42066,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714743000000},"adr":0,"listingDate":1462507200000,"adjPreClose":23.27,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":23.58,"preClose":23.27,"latestTime":"04:25 EDT","volume":47,"amount":1108.579929,"timestamp":1714724749590},"postHourTrading":{"tag":"盘后","latestPrice":23.28,"preClose":23.27,"latestTime":"19:06 EDT","volume":58747,"amount":1366365.46,"timestamp":1714691200139},"volumeRatio":0.9095837014394051,"optionData":{"bulkOrders":[{"symbol":"NTLA","call":false,"expireDate":1721361600000,"strike":"20.0","timestamp":1714665065435,"price":1.5800000429153442,"volume":2500,"amount":395000,"type":"-"},{"symbol":"NTLA","call":false,"expireDate":1715918400000,"strike":"22.5","timestamp":1714664609846,"price":1.2000000476837158,"volume":1500,"amount":180000,"type":"+"}]}},"requestUrl":"/m/hq/s/NTLA/tweets","defaultTab":"tweets","newsList":[{"id":"2432701185","title":"Intellia Therapeutics, Inc.盘中异动 急速拉升5.02%报22.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432701185","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432701185?lang=zh_cn&edition=full","pubTime":"2024-05-01 21:37","pubTimestamp":1714570679,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日21时37分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Cytomx Therapeutics, Inc.、Palisade Bio, Inc.、Tg Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为443.08%、38.73%、15.94%，振幅较大的相关个股有Promis Neurosciences Inc.、Carmell Corporation、Cytomx Therapeutics, Inc.，振幅分别为23.46%、21.50%、19.63%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012137597925a0ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012137597925a0ac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432306173","title":"Intellia Therapeutics Inc    预计每股亏损 1.38 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432306173","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432306173?lang=zh_cn&edition=full","pubTime":"2024-05-01 01:22","pubTimestamp":1714497741,"startTime":"0","endTime":"0","summary":"   * Intellia Therapeutics Inc     预计将在5月2日公布截至2024年3月31日的财报(估计)，季度收入将出现下降。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司的营收预计将从去年同期的1261万美元下降8.7%，至1150.4万美元。* LSEG 的分析师平均预计 Intellia Therapeutics Inc 每股亏损 1.38 美元。* 华尔街对 Intellia Therapeutics Inc 的 12 个月目标价中值为 70.00 美元，高于其上一次收盘价 21.98 美元。4月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431864707","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.06%报21.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431864707","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431864707?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:19","pubTimestamp":1714400366,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日22时19分，Intellia Therapeutics, Inc.股票出现波动，股价快速拉升5.06%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.99%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042922192687e84c24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042922192687e84c24&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430289441","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.03%报20.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430289441","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430289441?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:48","pubTimestamp":1714052918,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时48分，Intellia Therapeutics, Inc.股票出现异动，股价急速下跌5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.37%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425214839861e90d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425214839861e90d7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427188660","title":"Intellia Therapeutics, Inc.盘中异动 急速跳水5.03%报23.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427188660","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427188660?lang=zh_cn&edition=full","pubTime":"2024-04-16 00:32","pubTimestamp":1713198756,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日00时32分，Intellia Therapeutics, Inc.股票出现异动，股价大幅下挫5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041600323687e8080e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041600323687e8080e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424049823","title":"Intellia Therapeutics, Inc.盘中异动 急速跳水5.03%报25.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424049823","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424049823?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:50","pubTimestamp":1712065815,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时50分，Intellia Therapeutics, Inc.股票出现波动，股价快速下挫5.03%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022150157a50b693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022150157a50b693&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419986569","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.20%报27.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419986569","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419986569?lang=zh_cn&edition=full","pubTime":"2024-03-14 23:09","pubTimestamp":1710428998,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日23时09分，Intellia Therapeutics, Inc.股票出现异动，股价大幅跳水5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.61%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031423095887e78f8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031423095887e78f8f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417425933","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417425933","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417425933?lang=zh_cn&edition=full","pubTime":"2024-03-06 03:10","pubTimestamp":1709665831,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日03时10分，Intellia Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.48%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030603103179178cc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030603103179178cc2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416600642","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416600642","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416600642?lang=zh_cn&edition=full","pubTime":"2024-03-01 23:21","pubTimestamp":1709306485,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日23时21分，Intellia Therapeutics, Inc.股票出现异动，股价快速上涨5.20%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.76%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012321257a48980e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012321257a48980e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415552941","title":"Intellia Therapeutics, Inc.盘中异动 早盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2415552941","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415552941?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:48","pubTimestamp":1709218089,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时48分，Intellia Therapeutics, Inc.股票出现异动，股价大幅上涨5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.17%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922480987e74e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922480987e74e76&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414857362","title":"Intellia Therapeutics Inc盘中异动 急速上涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414857362","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414857362?lang=zh_cn&edition=full","pubTime":"2024-02-27 04:27","pubTimestamp":1708979241,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日04时27分，Intellia Therapeutics Inc股票出现波动，股价快速上涨5.10%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.78%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022704272187e73358&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022704272187e73358&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414992650","title":"Intellia Therapeutics Inc2023财年实现净利润-4.81亿美元，同比减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414992650","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414992650?lang=zh_cn&edition=full","pubTime":"2024-02-26 00:21","pubTimestamp":1708878062,"startTime":"0","endTime":"0","summary":"12月31日，Intellia Therapeutics Inc公布财报，公告显示公司2023财年净利润为-4.81亿美元，同比减少1.48%；其中营业收入为36.28百万美元，同比减少30.39%，每股基本收益为-5.42美元。从资产负债表来看，Intellia Therapeutics Inc总负债2.51亿美元，其中短期债务18.60百万美元，资产负债比为5.19，流动比率为8.68。机构评级：截至2023年12月31日，当前有23家机构对Intellia Therapeutics Inc目标价做出预测，其中目标均价为68.74美元，其中最低目标价为24.00美元，最高目标价为144.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600210681b6075a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600210681b6075a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413795485","title":"Intellia Therapeutics Inc盘中异动 早盘股价大跌5.04%报25.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413795485","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413795485?lang=zh_cn&edition=full","pubTime":"2024-02-24 00:14","pubTimestamp":1708704846,"startTime":"0","endTime":"0","summary":"北京时间2024年02月24日00时14分，Intellia Therapeutics Inc股票出现异动，股价大幅下挫5.04%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.56%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224001406861d7f32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224001406861d7f32&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413719217","title":"Intellia Therapeutics Inc盘中异动 早盘大幅跳水5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413719217","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413719217?lang=zh_cn&edition=full","pubTime":"2024-02-22 23:21","pubTimestamp":1708615266,"startTime":"0","endTime":"0","summary":"北京时间2024年02月22日23时21分，Intellia Therapeutics Inc股票出现波动，股价急速下挫5.02%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.75%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022223210687e72484&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022223210687e72484&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411154714","title":"BUZZ-Intellia与ReCode合作治疗遗传病，业绩攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2411154714","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411154714?lang=zh_cn&edition=full","pubTime":"2024-02-15 23:49","pubTimestamp":1708012163,"startTime":"0","endTime":"0","summary":"    2月15日 - ** 基因编辑公司Intellia Therapeutics   股价上涨2.8%至29.06美元 ** 该公司称  它正在与总部位于加利福尼亚州的 ReCode Therapeutics 公司合作开发治疗囊性纤维化的新型疗法** 公司将负责基因编辑战略，而 ReCode 则负责临床前和临床开发以及商业化。** CF是一种遗传疾病，会导致各种器官积聚大量粘液** 包括本交易日在内，该公司股价在过去12个月中下跌了30.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411813465","title":"Intellia Therapeutics Inc盘中异动 大幅上涨5.03%报27.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411813465","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411813465?lang=zh_cn&edition=full","pubTime":"2024-02-15 00:54","pubTimestamp":1707929666,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日00时54分，Intellia Therapeutics Inc股票出现波动，股价急速上涨5.03%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.54%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215005426861d540b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215005426861d540b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411368045","title":"Intellia Therapeutics Inc盘中异动 早盘股价大跌5.40%报28.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411368045","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411368045?lang=zh_cn&edition=full","pubTime":"2024-02-13 22:32","pubTimestamp":1707834730,"startTime":"0","endTime":"0","summary":"北京时间2024年02月13日22时32分，Intellia Therapeutics Inc股票出现异动，股价快速跳水5.40%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.66%。其相关个股中，Biodexa Pharmaceuticals Plc、Bioxcel Therapeutics Inc、联拓生物涨幅较大，Biodexa Pharmaceuticals Plc、Adial Pharmaceuticals Inc、Kintara Therapeutics Inc较为活跃，换手率分别为296.82%、82.26%、30.14%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Biovie Inc、Rhythm Pharmaceuticals Inc，振幅分别为12.41%、12.28%、10.90%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402132232108188eb60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402132232108188eb60&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2410572583","title":"Intellia Therapeutics Inc盘中异动 下午盘大幅拉升5.18%报27.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2410572583","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2410572583?lang=zh_cn&edition=full","pubTime":"2024-02-09 02:58","pubTimestamp":1707418727,"startTime":"0","endTime":"0","summary":"北京时间2024年02月09日02时58分，Intellia Therapeutics Inc股票出现波动，股价大幅拉升5.18%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.32%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia专注于使用这项技术来治疗基因定义的疾病。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240209025847861d4c55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240209025847861d4c55&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2408471987","title":"Intellia Therapeutics Inc盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2408471987","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2408471987?lang=zh_cn&edition=full","pubTime":"2024-02-02 23:02","pubTimestamp":1706886172,"startTime":"0","endTime":"0","summary":"北京时间2024年02月02日23时02分，Intellia Therapeutics Inc股票出现异动，股价快速下挫5.03%。Intellia Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.95%。Intellia Therapeutics Inc公司简介：Intellia Therapeutics是一家专注于开发基于CRISPR/ cas9的治疗方法的基因编辑公司。Intellia已经与几家公司建立了合作关系，以推进其产品线，包括窄护城河Regeneron和宽护城河Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402022302537a40e44b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402022302537a40e44b&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":0.1623},{"period":"1month","weight":-0.0729},{"period":"3month","weight":-0.0799},{"period":"6month","weight":-0.1909},{"period":"1year","weight":-0.3968},{"period":"ytd","weight":-0.2368}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014871},{"month":2,"riseRate":0.75,"avgChangeRate":0.078068},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040105},{"month":4,"riseRate":0.375,"avgChangeRate":-0.074095},{"month":5,"riseRate":0.375,"avgChangeRate":0.041777},{"month":6,"riseRate":0.875,"avgChangeRate":0.235553},{"month":7,"riseRate":0.5,"avgChangeRate":0.003735},{"month":8,"riseRate":0.625,"avgChangeRate":0.047366},{"month":9,"riseRate":0.125,"avgChangeRate":-0.068112},{"month":10,"riseRate":0.25,"avgChangeRate":-0.059832},{"month":11,"riseRate":0.625,"avgChangeRate":0.121561},{"month":12,"riseRate":0.375,"avgChangeRate":-0.073139}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}